Healthcare Industry News: breast cancer
News Release - March 19, 2013
bioTheranostics Adds Chief Medical Officer & Vice President of Medical, Clinical & Regulatory AffairsSAN DIEGO--(Healthcare Sales & Marketing Network)--bioTheranostics, Inc., a leading provider of molecular diagnostic solutions for metastatic cancer, today announced the appointment of Michael C. Dugan, M.D., as chief medical officer, and Catherine Schnabel, Ph.D., as vice president of medical, clinical, and regulatory affairs.
Richard Ding, CEO of bioTheranostics, said Drs. Dugan and Schnabel will play important roles in delivering bioTheranostics’ precision medicine products for cancer patients. These include diagnosis of primary tumor sites with its industry-leading CancerTYPE ID® molecular classifier, predictive biomarker testing with PRÉCIS® Precision Medicine biomarker profiles, and quantifying the risk of breast cancer recurrence with its breast cancer IndexSM.
“It is my great pleasure to have Drs. Dugan and Schnabel on our team,” Ding said. “Their combined expertise in molecular diagnostics, pathology, medical affairs, and clinical research will be instrumental as we work to provide solutions for metastatic cancer through the development of innovative molecular diagnostic tests.”
Ding said Dr. Dugan will be responsible for delivering high-quality testing services and establishing partnerships with pathology practices nationwide via collaboration with bioTheranostics’ commercial team. “This is a unique opportunity to bring Dr. Dugan on board, with his extensive experience in clinical, industry, and academic pathology settings,” Ding said.
Prior to joining bioTheranostics, Dr. Dugan was vice president and chief medical officer at Roche Molecular Systems, Inc., and held senior pathology/laboratory and management positions at Genzyme Genetics and Specialty Laboratories, Inc. He also was chief of pathology and medical director of clinical laboratories at UCLA Medical Center, Santa Monica, as well as a staff pathologist for Affiliated Pathologists Medical Group. He has served as assistant professor of pathology at both UCLA and Wayne State University School of Medicine. Dr. Dugan earned his bachelor’s degree in biology from the University of Notre Dame and his medical degree from the University of Arizona College of Medicine. He completed postgraduate training at Yale-New Haven Hospital, Children’s Hospital Los Angeles, and UCLA.
As vice president of clinical, medical, and regulatory affairs, Dr. Schnabel will be responsible for the development and execution of clinical studies, medical strategy, and regulatory plans. She came to bioTheranostics in 2009 with more than 12 years of experience as an industry scientist in pharmaceutical, clinical, and diagnostics research. Her previous experience includes medical affairs at Amylin Pharmaceuticals and research roles at Genoptix and Genentech. Dr. Schnabel received her Ph.D. training in molecular and cellular biology at Rutgers University’s Center of Advanced Biotechnology and Medicine, and was a postdoctoral fellow at the National Institutes of Health and the Leukemia and Lymphoma Society at Stanford University.
“Dr. Schnabel has been instrumental in establishing best-in-class clinical evidence for bioTheranostics’ products,” Ding said. “Her expanded leadership role will ensure that our outstanding science will continue to be translated into clinical success.”
bioTheranostics is the leading solution provider for metastatic cancer management, leveraging its unique expertise in expression profiling to develop a growing array of molecular diagnostic tests for cancer patients. The company operates a CLIA-certified, CAP-accredited diagnostic laboratory to perform its proprietary tests: the CancerTYPE ID® molecular classification test; PRÉCIS® Precision Medicine, which includes biomarker profiles for non-small cell lung, colorectal, and other cancers; and breast cancer IndexSM, which quantifies risk of recurrence of estrogen receptor-positive, lymph node-negative breast cancer. bioTheranostics, a bioMérieux company, is based in San Diego. For more information, visit www.biotheranostics.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.